Abvc Biopharma (ABVC) Current Assets (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Current Assets came in at $648848.0 in Q1 2026, down 55.85% YoY from $1.5 million in Q1 2025, and down 74.06% on a QoQ basis from $2.5 million in Q4 2025.
Abvc Biopharma (ABVC) Current Assets (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 16 years of Current Assets data on file, last reported at $648848.0 in Q1 2026.
- Quarterly Current Assets fell 55.85% year-over-year to $648848.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $648848.0 (down 55.85% YoY) and the FY2025 annual result came in at $2.5 million, up 14.75% from the prior year.
- Current Assets eased to $648848.0 in Q1 2026, from $2.5 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $9.8 million in Q2 2022 to a low of $648848.0 in Q1 2026.
- A 5-year average of $3.1 million and a median of $2.5 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets surged 169.86% — and 2023, when it tumbled 78.25%.
- Tracing ABVC's Current Assets over 5 years: stood at $3.0 million in 2022, then tumbled by 44.54% to $1.7 million in 2023, then surged by 31.58% to $2.2 million in 2024, then grew by 14.75% to $2.5 million in 2025, then tumbled by 74.06% to $648848.0 in 2026.
- The last three Current Assets figures came in at $648848.0 (Q1 2026), $2.5 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 1.76 Bn |
| 10 | Abvc Biopharma | 24.23 Mn | 24.23 Mn | - | 411,729.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 411,729.00 |
| Mar 31, 2026 | 648,848.00 |
| Dec 31, 2025 | 2.50 Mn |
| Sep 30, 2025 | 3.31 Mn |
| Jun 30, 2025 | 2.77 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Sep 30, 2024 | 2.17 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | 1.66 Mn |
| Sep 30, 2023 | 2.49 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 3.48 Mn |
| Dec 31, 2022 | 2.99 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Jun 30, 2022 | 9.79 Mn |
| Mar 31, 2022 | 7.99 Mn |
| Dec 31, 2021 | 7.65 Mn |
| Sep 30, 2021 | 7.11 Mn |